Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer

Celgene, Corp., Nuvilex, Inc. on Similar Path in Fight Against Pancreatic Cancer 
NEW YORK, NY -- (Marketwire) -- 03/05/13 --  Two biotechnology
companies, NASDAQ's Celgene, Corp. and Nuvilex, Inc. (OTCQB: NVLX),
are hot on the heels of a third biotech that has dominated the
pancreatic drug market since 1996. Stock House Group, a research and
content development investor relations firm, takes a look at the
amazing results that both are delivering and tells a story that the
NYSE's Eli Lilly and Company should start giving a little more
In late January, those with advanced stage pancreatic cancer received
some good news when Celgene, Corp., an international biotechnology
company, announced the results of its large scale phase III trial at
the 2013 Gastrointestinal Cancers Symposium of the American Society
of Clinical Oncology (ASCO), held in San Francisco.  
Pancreatic cancer is difficult to diagnose and treat until it is at
an advanced stage. Survival of patients with advanced, inoperable
pancreatic cancer is usually only several weeks or a few months. The
National Cancer Institute estimates that, in the U.S. alone, 45,220
new cases of pancreatic cancer will be diagnosed in 2013 and that
38,460 deaths will be attributable to the dreaded disease this year. 
But, like two prize fighters, a pair of biotech companies, is
steadfast in the battle against a common enemy -- pancreatic cancer.
Both have presented astounding results that leave one to think, we
may be extremely close to turning the corner in the fight against
this brutal disease. 
David and Goliath Strengthen Hand vs. Opponent
 One is a Goliath in
the biotech world, leaving the other to take on the role of David as
a much smaller biotech, but for those who suffer with pancreatic
cancer, they don't see size, they see results. And, the results these
two companies are delivering are providing much needed hope to
patients, interestingly though, from two completely different
Read the full feature news article at
About Stock House Group
 Stock House Group is a full service
Investment Relations firm specializing in Awareness, Research, and
Content Development. The firm offers a platform to CEOs to develop
their story through the press, Research Reports, and CEO Interviews.
At the same time, we are building a library of Research for Investors
to use while doing their due diligence on micro, small and large cap
Stock House Group
Press spacebar to pause and continue. Press esc to stop.